110 related articles for article (PubMed ID: 12149314)
21. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
[TBL] [Abstract][Full Text] [Related]
22. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
[TBL] [Abstract][Full Text] [Related]
23. Serum HER-2/neu: a new predictive marker.
Voss A; Neumann R
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):584-5. PubMed ID: 12503824
[No Abstract] [Full Text] [Related]
24. The prognostic and predictive values of ECD-HER-2.
Hait WN
Clin Cancer Res; 2001 Sep; 7(9):2601-4. PubMed ID: 11555568
[TBL] [Abstract][Full Text] [Related]
25. [Serum her-2/neu level and related factors in patients with breast cancer].
Yuan P; Xu BH; Zhang C; Qi J
Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
[TBL] [Abstract][Full Text] [Related]
26. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
[TBL] [Abstract][Full Text] [Related]
27. [Serum HER-2 determination using a centauer HER-2/neu kit (CLIA method) in metastatic breast cancer].
Kan N; Yoshikawa S
Gan To Kagaku Ryoho; 2009 May; 36(5):779-83. PubMed ID: 19461177
[TBL] [Abstract][Full Text] [Related]
28. Current treatment of HER 2+ metastatic breast cancer.
Burcombe R
Br J Nurs; 2017 Sep; 26(Sup16a):S7-S14. PubMed ID: 28981328
[TBL] [Abstract][Full Text] [Related]
29. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
Schulze G
Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
[TBL] [Abstract][Full Text] [Related]
30. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
Altundag K; Altundag O
J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
[No Abstract] [Full Text] [Related]
31. Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
Esteva FJ
Oncologist; 2008 Apr; 13(4):370-2. PubMed ID: 18448550
[No Abstract] [Full Text] [Related]
32. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
33. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.
Bethune-Volters A; Labroquere M; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
Anticancer Res; 2004; 24(2C):1083-9. PubMed ID: 15154627
[TBL] [Abstract][Full Text] [Related]
35. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study.
Hoopmann M; Neumann R; Tanasale T; Schöndorf T
Anticancer Res; 2003; 23(2A):1031-4. PubMed ID: 12820343
[TBL] [Abstract][Full Text] [Related]
36. Concentration of serum HER-2/neu as a prognostic factor in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).
Purwanto I; Kurnianda J; Hariadi KW; Harijadi ; Aryandono T; Setiaji K; Harianti MS; Haryana SM
Acta Med Indones; 2011 Jan; 43(1):23-8. PubMed ID: 21339542
[TBL] [Abstract][Full Text] [Related]
37. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
[TBL] [Abstract][Full Text] [Related]
38. [An investigation of extracellular HER-2/NEU domain level in blood serum from breast cancer patients].
Korytova LI; Masliukova EA; Ovchinnikov IV; Filipenko MO; Korytov OV; Kudaĭbergenova AG
Vopr Onkol; 2010; 56(1):62-5. PubMed ID: 20361618
[TBL] [Abstract][Full Text] [Related]
39. HER-2/neu diagnostics in breast cancer.
Carney WP; Leitzel K; Ali S; Neumann R; Lipton A
Breast Cancer Res; 2007; 9(3):207. PubMed ID: 17561991
[TBL] [Abstract][Full Text] [Related]
40. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.
Ciocca DR; Gago FE; Fanelli MA; Calderwood SK
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):32-40. PubMed ID: 17049840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
